• 1
    American Society of Addiction Medicine. Definition of Addiction. Available at (Short Definition of Addiction, last accessed on 27 June 2012).
  • 2
    Block JJ. Issues for DSM-V: internet addiction. Am J Psychiatry 2008; 165: 306307.
  • 3
    Ifland JR, Preuss HG, Marcus MT, Rourke KM, Taylor WC, Burau K, Jacobs WS, Kadish W, Manso G. Refined food addiction: a classic substance use disorder. Med Hypotheses 2009; 72: 518526.
  • 4
    Potenza MN, Fiellin DA, Heninger GR, Rounsaville BJ, Mazure CM. Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 2002; 17: 721732.
  • 5
    Mick TM, Hollander E. Impulsive-compulsive sexual behavior. CNS Spectr 2006; 11: 944955.
  • 6
    Kozlowski LT, Mann RE, Wilkinson DA, Poulos CX. ‘Cravings’ are ambiguous: ask about urges or desires. Addict Behav 1989; 14: 443445.
  • 7
    Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, Jayne M, Ma Y, Pradhan K, Wong C, Swanson JM. Cognitive control of drug craving inhibits brain reward regions in cocaine abusers. Neuroimage 2010; 49: 25362543.
  • 8
    World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders – Diagnostic Criteria for Research. Geneva: WHO, 1993.
  • 9
    American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 2000.
  • 10
    Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry 2001; 58: 334341.
  • 11
    Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, Yucel M. Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments. Drugs 2011; 71: 827840.
  • 12
    Pelchat ML. Of human bondage: food craving, obsession, compulsion, and addiction. Physiol Behav 2002; 76: 347352.
  • 13
    Rosenberg H. Clinical and laboratory assessment of the subjective experience of drug craving. Clin Psychol Rev 2009; 29: 519534.
  • 14
    Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 2006; 63: 324331.
  • 15
    Huang MC, Chen CH, Liu HC, Chen CC, Ho CC, Leu SJ. Differential patterns of serum brain-derived neurotrophic factor levels in alcoholic patients with and without delirium tremens during acute withdrawal. Alcohol Clin Exp Res 2011; 35: 126131.
  • 16
    Hilburn C, Nejtek VA, Underwood WA, Singh M, Patel G, Gangwani P, Forster MJ. Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine? Neuropsychiatr Dis Treat 2011; 7: 357364.
  • 17
    Heberlein A, Dursteler-MacFarland KM, Lenz B, Frieling H, Grosch M, Bonsch D, Kornhuber J, Wiesbeck GA, Bleich S, Hillemacher T. Serum levels of BDNF are associated with craving in opiate-dependent patients. J Psychopharmacol 2011; 25: 14801484.
  • 18
    Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep 2011; 13: 398405.
  • 19
    O'Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005; 162: 14231431.
  • 20
    Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behavioral and brain functions. Behav Brain Funct 2010; 6: 24.
  • 21
    Zweifel LS, Parker JG, Lobb CJ, Rainwater A, Wall VZ, Fadok JP, Darvas M, Kim MJ, Mizumori SJ, Paladini CA, Phillips PE, Palmiter RD. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proc Natl Acad Sci U S A 2009; 106: 72817288.
  • 22
    Blythe SN, Atherton JF, Bevan MD. Synaptic activation of dendritic AMPA and NMDA receptors generates transient high-frequency firing in substantia nigra dopamine neurons in vitro. J Neurophysiol 2007; 97: 28372850.
  • 23
    Jhou TC, Geisler S, Marinelli M, Degarmo BA, Zahm DS. The mesopontine rostromedial tegmental nucleus: a structure targeted by the lateral habenula that projects to the ventral tegmental area of Tsai and substantia nigra compacta. J Comp Neurol 2009; 513: 566596.
  • 24
    Lavezzi HN, Zahm DS. The mesopontine rostromedial tegmental nucleus: an integrative modulator of the reward system. Basal Ganglia 2011; 1: 191200.
  • 25
    Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci 2007; 8: 844858.
  • 26
    Landsberg R, Taintor Z, Plumb M, Amico L, Wicks N. An analysis of naltrexone use – its efficacy, safety and potential. NIDA Res Monogr 1976; 9: 106113.
  • 27
    Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973; 28: 784791.
  • 28
    Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 185.
  • 29
    Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry 2011; 12: 160187.
  • 30
    Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192213.
  • 31
    Sideroff SI, Charuvastra VC, Jarvik ME. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 1978; 5: 415423.
  • 32
    Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci 1980; 26: 679688.
  • 33
    Harris RA, Erickson CK. Alteration of ethanol effects by opiate antagonists. Curr Alcohol 1979; 5: 1728.
  • 34
    O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992; 49: 881887.
  • 35
    Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876880.
  • 36
    Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998; 18: 1066310671.
  • 37
    Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 17341739.
  • 38
    O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res 2007; 31: 625634.
  • 39
    Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O'Malley SS, Krystal JH. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry 2007; 61: 12901295.
  • 40
    Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004; 24: 421428.
  • 41
    Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719724.
  • 42
    Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, Kallio A, Makela R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007; 31: 11791187.
  • 43
    Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001; 26: 167180.
  • 44
    Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict 2004; 13: 333341.
  • 45
    Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009; 18: 356362.
  • 46
    Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 1998; 139: 4452.
  • 47
    Jayaram-Lindstrom N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008; 33: 18561863.
  • 48
    Jayaram-Lindstrom N, Wennberg P, Beck O, Franck J. An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry 2005; 59: 167171.
  • 49
    Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008; 165: 14421448.
  • 50
    Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010; 20: 823828.
  • 51
    King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 2006; 8: 671682.
  • 52
    David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2006; (4): CD003086.
  • 53
    Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 1999; 18: 3140.
  • 54
    Cooper ZD, Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl) 2010; 211: 141148.
  • 55
    Recant L, Voyles NR, Luciano M, Pert CB. Naltrexone reduces weight gain, alters ‘beta-endorphin’, and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1980; 1: 309313.
  • 56
    Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985; 38: 419422.
  • 57
    Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C. A controlled trial of naltrexone in obese humans. Int J Obes 1985; 9: 347353.
  • 58
    Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011; 19: 110120.
  • 59
    Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595605.
  • 60
    Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49: 914921.
  • 61
    Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008; 69: 783789.
  • 62
    Lahti T, Halme JT, Pankakoski M, Sinclair D, Alho H. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull 2010; 43: 3544.
  • 63
    Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry 2010; 197: 330331.
  • 64
    Bostwick JM, Bucci JA. Internet sex addiction treated with naltrexone. Mayo Clin Proc 2008; 83: 226230.
  • 65
    Lobmaier PP, Kunoe N, Gossop M, Waal H. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther 2011; 17: 629636.
  • 66
    Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Fohr J, Tuomola P, Kuoppasalmi K, Kiviniemi V, Zwartau E. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012; 169: 531536.
  • 67
    O'Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati HM. Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. Am J Addict 2011; 20: 0612.
  • 68
    Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998; 22: 802809.
  • 69
    Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 2010; 9: 177188.
  • 70
    Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 2005; 52: (Suppl.): 284290.
  • 71
    Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med 2007; 1: 115125.
  • 72
    Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9): CD004332.
  • 73
    Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001; 36: 413418.
  • 74
    Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin DW, Sparkman T, Sharkoski T, O'Brien CP. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009; 34: 581586.
  • 75
    Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O'Brien CP. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011; 36: 217221.
  • 76
    McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, McCoy J, Keck PE, Jr, Hudson JI. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 2011; 44: 8190.
  • 77
    Dannon PN, Rosenberg O, Schoenfeld N, Kotler M. Acamprosate and baclofen were not effective in the treatment of pathological gambling: preliminary blind rater comparison study. Front Psychiatry 2011; 2: 33.
  • 78
    Azevedo AA, Figueiredo RR. Tinnitus treatment with acamprosate: double-blind study. Braz J Otorhinolaryngol 2005; 71: 618623.
  • 79
    Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol 2011; 21: 565569.
  • 80
    Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010; 71: 634648.
  • 81
    Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, Pham T, Stock C, Dickinson R, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Li MD, Johnson BA. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 2012; 107: 12971306.
  • 82
    Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, Capece JA, Karvois D. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 13351341.
  • 83
    McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61: 10391048.
  • 84
    Claudino AM, de Oliveira IR, Appolinario JC, Cordas TA, Duchesne M, Sichieri R, Bacaltchuk J. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007; 68: 13241332.
  • 85
    Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, Lahmann C, Leiberich PK, Krawczyk J, Kettler C, Rother WK, Loew TH, Nickel MK. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005; 38: 295300.
  • 86
    Hald J, Jacobsen E. A drug sensitizing the organism to ethyl alcohol. Lancet 1948; 2: 10011004.
  • 87
    Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I. Disulfiram treatment of alcoholism. A Veterans Administration Cooperative Study. JAMA 1986; 256: 14491455.
  • 88
    Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26: 290302.
  • 89
    Johnson BA. Medication treatment of different types of alcoholism. Am J Psychiatry 2010; 167: 630639.
  • 90
    Closser MH, Kosten TR. Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics. Recent Dev Alcohol 1992; 10: 115128.
  • 91
    Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 2000; 95: 13351349.
  • 92
    Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93: 713727.
  • 93
    Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 264272.
  • 94
    Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 2009; 9: 175187.
  • 95
    Schroeder JP, Cooper DA, Schank JR, Lyle MA, Gaval-Cruz M, Ogbonmwan YE, Pozdeyev N, Freeman KG, Iuvone PM, Edwards GL, Holmes PV, Weinshenker D. Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase. Neuropsychopharmacology 2010; 35: 24402449.
  • 96
    Yao L, Fan P, Arolfo M, Jiang Z, Olive MF, Zablocki J, Sun HL, Chu N, Lee J, Kim HY, Leung K, Shryock J, Blackburn B, Diamond I. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat Med 2010; 16: 10241028.
  • 97
    Nagendra SN, Faiman MD, Davis K, Wu JY, Newby X, Schloss JV. Carbamoylation of brain glutamate receptors by a disulfiram metabolite. J Biol Chem 1997; 272: 2424724251.
  • 98
    Kaul S, Faiman MD, Lunte CE. Determination of GABA, glutamate and carbamathione in brain microdialysis samples by capillary electrophoresis with fluorescence detection. Electrophoresis 2011; 32: 284291.
  • 99
    Mutschler J, Buhler M, Grosshans M, Diehl A, Mann K, Kiefer F. Disulfiram, an option for the treatment of pathological gambling? Alcohol Alcohol 2010; 45: 214216.
  • 100
    Muller CA, Banas R, Heinz A, Hein J. Treatment of pathological gambling with disulfiram: a report of 2 cases. Pharmacopsychiatry 2011; 44: 8183.
  • 101
    Lin LZ, Lin J. Antabuse (disulfiram) as an affordable and promising anticancer drug. Int J Cancer 2011; 129: 12851286.
  • 102
    Sauna ZE, Shukla S, Ambudkar SV. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst 2005; 1: 127134.
  • 103
    Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17: 107116.
  • 104
    Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II – preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 6771.
  • 105
    Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504508.
  • 106
    Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 19151922.
  • 107
    Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011; 46: 312317.
  • 108
    Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 18491857.
  • 109
    Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2005; 40: 147150.
  • 110
    Pastor A, Jones DM, Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol 2012; 32: 266268.
  • 111
    Enserink M. Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy. Science 2011; 332: 653.
  • 112
    Rolland B, Bordet R, Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction 2012; 107: 848849.
  • 113
    Kahn R, Biswas K, Childress AR, Shoptaw S, Fudala PJ, Gorgon L, Montoya I, Collins J, McSherry F, Li SH, Chiang N, Alathari H, Watson D, Liberto J, Beresford T, Stock C, Wallace C, Gruber V, Elkashef A. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 2009; 103: 5964.
  • 114
    Gorsane MA, Kebir O, Hache G, Blecha L, Aubin HJ, Reynaud M, Benyamina A. Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. Subst Abus 2012; 33: 336349.
  • 115
    Assadi SM, Radgoodarzi R, Ahmadi-Abhari SA. Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial. BMC Psychiatry 2003; 3: 16.
  • 116
    Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2010; 211: 233244.
  • 117
    Franklin TR, Harper D, Kampman K, Kildea-McCrea S, Jens W, Lynch KG, O'Brien CP, Childress AR. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009; 103: 3036.
  • 118
    Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36: 7886.
  • 119
    LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, McRae A, Brady K. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006; 15: 105110.
  • 120
    LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas PW, Malcolm R. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007; 164: 11151117.
  • 121
    Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 389394.
  • 122
    Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010; 19: 187189.
  • 123
    Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011; 17: 211216.
  • 124
    Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62: 652657.
  • 125
    Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009; 66: 756763.
  • 126
    Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321327.
  • 127
    Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, Townsend J. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003; 254: 184192.
  • 128
    Kotlyar M, Drone D, Thuras P, Hatsukami DK, Brauer L, Adson DE, al'Absi M. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res 2011; 13: 492497.
  • 129
    Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008; 33: 11621170.
  • 130
    Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, De La Garza R, Newton T, Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 96: 222232.
  • 131
    Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH, Bridge P. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125131.
  • 132
    Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009; 18: 5364.
  • 133
    Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532546.
  • 134
    Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7: 106113.
  • 135
    Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000; 284: 963971.
  • 136
    Sell LA, Cowen PJ, Robson PJ. Ondansetron and opiate craving. A novel pharmacological approach to addiction. Br J Psychiatry 1995; 166: 511514.
  • 137
    Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, Li SH, Bloch DA, Methamphetamine Study Group. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol 2008; 11: 114.
  • 138
    Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, Mojsiak J, Li SH, Bloch DA. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006; 84: 256263.
  • 139
    Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 2007; 87: 19.
  • 140
    Winhusen T, Somoza E, Ciraulo DA, Harrer JM, Goldsmith RJ, Grabowski J, Coleman FS, Mindrum G, Kahn R, Osman S, Mezinskis J, Li SH, Lewis D, Horn P, Montgomery MA, Elkashef A. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend 2007; 91: 141148.